Delving into the Latest Updates on Guangdong Xiankangda Biotechnology Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Nervous System Diseases

CAR-T

Mesenchymal stem cell therapy

Natural Killer Cell Therapies

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	13
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

CAR-T	10
Mesenchymal stem cell therapy	2
CAR-NK	1
Universal CAR-T	1
Natural Killer Cell Therapies	1

Top 5 Target	Count

CLDN18.2(Claudin 18.2)	5
nectin-4	2

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

9

2

Phase 1 Clinical

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XKDCT-293 ( nectin-4 )	Advanced breast cancer More	Phase 1
CT-225 ( CLDN18.2 )	CLDN18.2 positive Solid Tumors More	Phase 1
PANK-003	Solid tumor More	Clinical
ST-002(Guangdong Xiankangda Biotechnology)	Ischemic stroke More	Clinical
ST-001 (Xiankangda)	Osteoarthritis, Knee More	Clinical